Monoclonal antibody therapeutics are being used for treatment of a wide array of diseases, specially in therapeutic areas such as oncology, immunology (including autoimmune and inflammatory diseases, as well as, transplant rejection) and neuroscience. The development of these new molecular agents, successfully directed to specific cellular targets, is playing a crucial role in the pharmaceutical industry. This trend shows the strong focus of top biopharmaceutical companies in biologics, including monoclonal antibody therapeutics. This research service discusses the emerging trends in monoclonal antibody therapeutics on a global scale, through a detailed strategic assessment of the industry environment.
Research Scope
Research Methodology
Key Findings
Technology Snapshot – Multiple Segmentation
Industry Overview – Main Innovations
Industry Overview – Main Innovators
Technology Roadmap Toward Precision Medicine
Therapeutic Areas and Clinical Indications
Molecular Agents and Cell Targets
Developmental Stage Focus
Market Potential
Market Evolution
Venture Capital Investment
Company Stage Investment Focus
Government Funding and Support
Worldwide Landscape
Key Drivers and Restraints
Key Technical and Business Challenges
Industry Assessment – Partnerships and Alliances
Stakeholder Assessment for Partnerships
Partnerships and Alliances Models
Partnerships and Collaborations
Partnerships and Collaborations (continued)
Partnerships and Collaborations (continued)
Patent Analysis
Patent publishing trends
Patent office-wise distribution
R&D Success and Key Performance Indicators
Analytical Hierarchy Process (AHP)
Analytical Hierarchy Process (AHP)
Analytical Hierarchy Process (AHP)
Analytical Hierarchy Process (AHP)
Analytical Hierarchy Process (AHP)
Analytical Hierarchy Process (AHP)
Analytical Hierarchy Process (AHP)
Analytical Hierarchy Process (AHP)
Analytical Hierarchy Process (AHP)
Contacts
Contacts (continued)
Strategic R&D Pipeline – The Road Ahead
R&D Pipeline Assessment
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
R&D Pipeline Assessment (continued)
Product Line Assessment
Product Line Assessment (continued)
Product Line Assessment (continued)
Product Line Assessment (continued)
Product Line Assessment (continued)
Product Line Assessment (continued)
Product Line Assessment (continued)
Product Line Assessment (continued)
Product Line Assessment (continued)
Product Line Assessment (continued)
Abbreviations
Legal Disclaimer
The Frost & Sullivan Story
Value Proposition: Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.
Speak directly with our analytics experts for tailored recommendations.
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
Monoclonal antibody therapeutics are being used for treatment of a wide array of diseases, specially in therapeutic areas such as oncology, immunology (including autoimmune and inflammatory diseases, as well as, transplant rejection) and neuroscience. The development of these new molecular agents, successfully directed to specific cellular targets, is playing a crucial role in the pharmaceutical industry. This trend shows the strong focus of top biopharmaceutical companies in biologics, including monoclonal antibody therapeutics. This research service discusses the emerging trends in monoclonal antibody therapeutics on a global scale, through a detailed strategic assessment of the industry environment.
| Deliverable Type | Technology Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Cecilia Van Cauwenberghe |
| Industries | Healthcare |
| WIP Number | D65E-01-00-00-00 |
| Is Prebook | No |
Advances in monoclonal antibody therapeutics
Advances in monoclonal antibody therapeutics
RELEASE DATE
29-Sep-2015
29-Sep-2015
REGION
Global
Global
Deliverable Type
Technology Research
Technology Research
Research Code: D65E-01-00-00-00
SKU: MX0150-GL-TR_18357
$4,950.00
In stock
SKU
MX0150-GL-TR_18357